IDRA bad investment
Be aware that FDA and institutional Investors don't give any value for any kind of trial which is not controlled and single armed. IDRA has only Ph-3 meeting that requirements but the result of that will be known only in 2021. Until then , there is nothing which can prove that TILSO is contributing anything towards any improved ORR or OS. That is why it is a under $2 stock and will remain here for rest of the year. The recent PP by BB has 4 transaction which are event based and most likely IDRA will not get any amount until Ph-3 data is turned over in 2021 other than upfront 10m. Read the 8-k fillings in details to understand clearly. So, don't get you money stuck here for the entire year 2020, that is my advice but it is up to you..